Table 4. Correlation of HIF-1α, MDR1, and LAPTM4B expression with clinico-pathological features of prostate cancer.
| Clinical-pathological Characteristics | ALL N (%) |
HIF-1α expression | MDR1 expression | LAPTM4B expression | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | p-value | Low | High | p-value | Low | High | p-value | |||
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | ||||||
| Stage | 0.05 | 0.400 | 0.05 | ||||||||
| I–II | 6 (28.5) | 3 (50.0) | 3 (50.0) | 5 (83.3) | 1 (20.0) | 3 (50.0) | 3 (50.0) | ||||
| III–IV | 15 (71.4) | 5 (33.3) | 10 (66.6) | 4 (26.6) | 11 (73.3) | 3 (20.0) | 12 (80.0) | ||||
| Metastasis | 0.014 | 0.357 | 0.018 | ||||||||
| Metastatic | 13 (66.6) | 4 (30.7) | 9 (69.2) | 6 (46.1) | 7 (53.8) | 3 (23.0) | 10 (76.9) | ||||
| Non-metastatic | 8 (33.3) | 4 (50.0) | 4 (50.0) | 3 (37.5) | 5 (62.5) | 3 (37.5) | 5 (62.5) | ||||
| Chemotherapy status | 0.029 | 0.048 | 0.476 | ||||||||
| Treatment naive | 7 (19.0) | 4 (57.1) | 3 (42.8) | 4 (57.1) | 3 (42.8) | 1 (14.2) | 6 (85.7) | ||||
| Pre-treated | 14 (80.9) | 4 (28.5) | 10 (71.4) | 5 (35.7) | 9 (64.2) | 5 (35.7) | 9 (64.2) | ||||
Notes:
The N shows the number of patients in each group. Where p value describes the significance and p < 0.05 shows the significance of results.